Cutia Therapeutics (HK:2487) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cutia Therapeutics has announced a voluntary update on its CFO and Executive Director, Mr. Huang Yuqing’s, recent purchase of an additional 35,000 company shares, with a total of 85,000 shares acquired in early October 2024 for roughly HK$1.17 million. This investment signifies Mr. Huang’s strong belief in the company’s future and he may consider increasing his stake further. The company assures that it retains sufficient public float in compliance with Hong Kong Exchange rules.
For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.